Jackson Hole Capital Partners LLC Invests $4.15 Million in Zoetis Inc. (NYSE:ZTS)

Jackson Hole Capital Partners LLC acquired a new position in Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,016 shares of the company's stock, valued at approximately $4,148,000. Zoetis accounts for approximately 1.1% of Jackson Hole Capital Partners LLC's holdings, making the stock its 23rd biggest holding.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company's stock valued at $2,147,730,000 after purchasing an additional 297,044 shares during the period. Northern Trust Corp raised its stake in Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company's stock valued at $1,068,804,000 after purchasing an additional 196,771 shares during the period. Bank of New York Mellon Corp raised its stake in Zoetis by 3.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,998,989 shares of the company's stock valued at $695,744,000 after purchasing an additional 150,918 shares during the period. Royal Bank of Canada raised its stake in Zoetis by 3.1% during the 3rd quarter. Royal Bank of Canada now owns 3,026,518 shares of the company's stock valued at $526,553,000 after purchasing an additional 91,713 shares during the period. Finally, Blair William & Co. IL raised its stake in Zoetis by 1.4% during the 3rd quarter. Blair William & Co. IL now owns 2,428,509 shares of the company's stock valued at $422,512,000 after purchasing an additional 32,918 shares during the period. Institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent analyst reports. Piper Sandler reissued an "overweight" rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays decreased their price objective on Zoetis from $260.00 to $230.00 and set an "overweight" rating on the stock in a report on Tuesday. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the stock a "buy" rating in a report on Wednesday, January 17th. Stifel Nicolaus decreased their price objective on Zoetis from $215.00 to $195.00 and set a "buy" rating on the stock in a report on Tuesday, April 2nd. Finally, StockNews.com cut Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $218.00.

Zoetis Trading Up 1.6 %

Shares of NYSE ZTS traded up $2.48 during trading hours on Thursday, hitting $153.36. 4,555,033 shares of the company traded hands, compared to its average volume of 3,093,786. The stock has a market capitalization of $70.14 billion, a price-to-earnings ratio of 30.25, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company's 50 day moving average price is $172.39 and its 200 day moving average price is $179.40. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis's dividend payout ratio is currently 33.93%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now owns 15,723 shares of the company's stock, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last quarter. 0.12% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.